Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other Non-Current Assets (2016 - 2025)

Sutro Biopharma's Other Non-Current Assets history spans 10 years, with the latest figure at $858000.0 for Q2 2025.

  • For Q2 2025, Other Non-Current Assets changed 0.12% year-over-year to $858000.0; the TTM value through Jun 2025 reached $858000.0, changed 0.12%, while the annual FY2024 figure was $858000.0, 75.95% down from the prior year.
  • Other Non-Current Assets for Q2 2025 was $858000.0 at Sutro Biopharma, roughly flat from $858000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.6 million in Q4 2023 and bottomed at $857000.0 in Q1 2024.
  • The 5-year median for Other Non-Current Assets is $872000.0 (2021), against an average of $1.0 million.
  • The largest annual shift saw Other Non-Current Assets surged 5713.33% in 2021 before it tumbled 75.95% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $872000.0 in 2021, then changed by 0.0% to $872000.0 in 2022, then skyrocketed by 309.06% to $3.6 million in 2023, then crashed by 75.95% to $858000.0 in 2024, then changed by 0.0% to $858000.0 in 2025.
  • Per Business Quant, the three most recent readings for STRO's Other Non-Current Assets are $858000.0 (Q2 2025), $858000.0 (Q1 2025), and $858000.0 (Q4 2024).